EP1917979A4 - Therapeutic agent for atrial fibrillation - Google Patents
Therapeutic agent for atrial fibrillationInfo
- Publication number
- EP1917979A4 EP1917979A4 EP06796612A EP06796612A EP1917979A4 EP 1917979 A4 EP1917979 A4 EP 1917979A4 EP 06796612 A EP06796612 A EP 06796612A EP 06796612 A EP06796612 A EP 06796612A EP 1917979 A4 EP1917979 A4 EP 1917979A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- atrial fibrillation
- therapeutic agent
- active ingredient
- atenolol
- verapamil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Abstract
Disclosed is a therapeutic agent for atrial fibrillation comprising an If current inhibitor, particularly (-)-N-[2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydro- isoquinoline-2-carbonyl)piperidino]ethyl]-4-fluorobenzamide monophosphate, as an active ingredient. This active ingredient has more preferred properties for use as a therapeutic agent for atrial fibrillation compared to verapamil (a Ca antagonist) and atenolol (a β-blocker) which have been conventionally used as the therapeutic agents for atrial fibrillation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005241403 | 2005-08-23 | ||
PCT/JP2006/316349 WO2007023775A1 (en) | 2005-08-23 | 2006-08-22 | Therapeutic agent for atrial fibrillation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1917979A1 EP1917979A1 (en) | 2008-05-07 |
EP1917979A4 true EP1917979A4 (en) | 2009-06-03 |
Family
ID=37771520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06796612A Withdrawn EP1917979A4 (en) | 2005-08-23 | 2006-08-22 | Therapeutic agent for atrial fibrillation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090247572A1 (en) |
EP (1) | EP1917979A4 (en) |
JP (1) | JPWO2007023775A1 (en) |
CA (1) | CA2617519A1 (en) |
WO (1) | WO2007023775A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010128525A2 (en) | 2009-05-04 | 2010-11-11 | Dinesh Shantilal Patel | A formulation of ivabradine for treating the cardiovascular disease |
WO2014179764A1 (en) * | 2013-05-03 | 2014-11-06 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2681862B1 (en) * | 1991-09-27 | 1993-11-12 | Adir Cie | NOVELS (BENZOCYCLOALKYL) ALKYLAMINES, THEIR PREPARATION PROCESS, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5595987A (en) * | 1994-07-22 | 1997-01-21 | The Trustees Of Columbia University In The City Of New York | Method of slowing ventricular arrhythmias using zatebradine |
JP2000302778A (en) * | 1999-04-27 | 2000-10-31 | Yamanouchi Pharmaceut Co Ltd | Isoquinolinone derivative or its salt |
CA2373880C (en) * | 1999-06-03 | 2009-04-07 | Yamanouchi Pharmaceutical Co., Ltd. | Isoquinoline derivatives or salts thereof |
DE19929076A1 (en) * | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | New indanyl-substituted benzenesulfonamide derivatives, as potassium channel blockers useful as safe antiarrhythmic agents, e.g. for treating atrial fibrillation or flutter |
DE10018401A1 (en) * | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Medicament for treating hypertrophy-related myocardial disease, containing bradycardic agent, preferably cilobradine, and optionally another cardiac drug |
MXPA03011330A (en) * | 2001-06-08 | 2004-12-06 | Johnson & Johnson | Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels. |
WO2003009839A1 (en) * | 2001-07-20 | 2003-02-06 | Karo Bio Ab | Benzofuranes and their use in the treatment of atrial fibrillation |
JP2005090957A (en) * | 2001-10-16 | 2005-04-07 | Mochida Pharmaceut Co Ltd | Screening method of auricular fibrillation remedy |
FR2834896B1 (en) * | 2002-01-23 | 2004-02-27 | Servier Lab | ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF IVABRADINE |
PT1362590E (en) * | 2002-07-25 | 2004-05-31 | Boehringer Ingelheim Pharma | USE OF CILOBRADINE OR OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE TREATMENT OR PREVENTION OF HEART FAILURE |
US20040138306A1 (en) * | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
TW200418468A (en) * | 2002-11-18 | 2004-10-01 | Solvay Pharm Gmbh | Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events |
WO2004058710A1 (en) * | 2002-12-25 | 2004-07-15 | Astellas Pharma Inc. | Novel benzamide derivatives and process for production thereof |
-
2006
- 2006-08-22 JP JP2007532100A patent/JPWO2007023775A1/en active Pending
- 2006-08-22 US US12/064,148 patent/US20090247572A1/en not_active Abandoned
- 2006-08-22 EP EP06796612A patent/EP1917979A4/en not_active Withdrawn
- 2006-08-22 WO PCT/JP2006/316349 patent/WO2007023775A1/en active Application Filing
- 2006-08-22 CA CA002617519A patent/CA2617519A1/en not_active Abandoned
Non-Patent Citations (8)
Title |
---|
CAMM A JOHN ET AL: "Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology.", DRUGS IN R&D 2003, vol. 4, no. 2, 2003, pages 83 - 89, XP009114122, ISSN: 1174-5886 * |
HEIDELBUCHEL HEIN ET AL: "Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence", CIRCULATION, vol. 89, no. 3, 1994, pages 1051 - 1059, XP002520357, ISSN: 0009-7322 * |
KHAN I A ET AL: "Acute ventricular rate control in atrial fibrillation and atrial flutter", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 97, no. 1, 1 October 2004 (2004-10-01), pages 7 - 13, XP004546164, ISSN: 0167-5273 * |
KUBOTA HIDEKI ET AL: "SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF 1-OXO-2(3-PIPERIDYL)-1,2, 3,4-TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES AS A NEW CLASS OF SPECIFIC BRADYCARDIC AGENTS POSSESSING If CHANNEL INHIBITORY ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON.; US, vol. 46, 1 January 2003 (2003-01-01), pages 4728 - 4740, XP002355168, ISSN: 0022-2623 * |
See also references of WO2007023775A1 * |
SIMPSON C S ET AL: "Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial.", AMERICAN HEART JOURNAL AUG 2001, vol. 142, no. 2, August 2001 (2001-08-01), pages E3, XP002520356, ISSN: 0002-8703 * |
YAMAZAKI KYOUHEI ET AL: "Negative chronotropic and dromotropic effects of E-4031, an I-Kr blocker, on the atrioventricular node in anesthetized dog hearts", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 297, no. 3, 1996, pages 233 - 239, XP002520355, ISSN: 0014-2999 * |
ZORN-PAULY K ET AL: "If in left human atrium: a potential contributor to atrial ectopy", CARDIOVASCULAR RESEARCH, OXFORD UNIVERSITY PRESS, vol. 64, no. 2, 1 November 2004 (2004-11-01), pages 250 - 259, XP004600501, ISSN: 0008-6363 * |
Also Published As
Publication number | Publication date |
---|---|
US20090247572A1 (en) | 2009-10-01 |
CA2617519A1 (en) | 2007-03-01 |
WO2007023775A1 (en) | 2007-03-01 |
EP1917979A1 (en) | 2008-05-07 |
JPWO2007023775A1 (en) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA06000013A (en) | Therapeutic agent for soft tissue sarcoma. | |
CA2400447A1 (en) | Kinase inhibitors | |
MXPA06000675A (en) | Quinolone derivative or salt thereof. | |
TW200505411A (en) | A formulation for chemical peeling | |
WO2003048081A3 (en) | Glycinamides as factor xa inhibitors | |
WO2001041701A3 (en) | The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist | |
WO2005030791A3 (en) | Isoquinolinone potassium channel inhibitors | |
WO2005019190A3 (en) | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors | |
WO2004032852A3 (en) | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists | |
AU2003245804A1 (en) | Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion | |
MXPA05009367A (en) | Opioid receptor antagonists. | |
WO2004047838A3 (en) | Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents | |
WO2004063151A3 (en) | Novel tyrosine kinase inhibitors | |
WO2003095455A3 (en) | Substituted pyrazolopyrimidines | |
WO2006034296A3 (en) | Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof | |
EP1816122A3 (en) | 3,4,5-substituted piperidines as therapeutic compounds | |
MXPA03009750A (en) | Chemical compounds. | |
AU2003239389A1 (en) | Opioid receptor antagonists | |
WO2008079873A3 (en) | Thiazolyl compounds useful as kinase inhibitors | |
UA87312C2 (en) | COMPOSITION FOR AEROSOL INHALATION OF β-AGONISTS | |
WO2006110173A3 (en) | Novel compounds | |
WO2009106599A3 (en) | Substituted piperidines as therapeutic compounds | |
EP1879027A4 (en) | Agent for preventing and treating pancreatitis | |
EP1917979A4 (en) | Therapeutic agent for atrial fibrillation | |
WO2005042021A3 (en) | Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080219 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090507 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090806 |